Willis Investment Counsel Purchases 1,102 Shares of Medpace Holdings, Inc. $MEDP

Willis Investment Counsel boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,957 shares of the company’s stock after acquiring an additional 1,102 shares during the quarter. Willis Investment Counsel owned 0.06% of Medpace worth $9,960,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of MEDP. Johnson Financial Group Inc. bought a new stake in shares of Medpace during the 2nd quarter worth $27,000. Jones Financial Companies Lllp purchased a new position in Medpace in the 2nd quarter worth approximately $30,000. Allied Private Wealth LLC bought a new stake in Medpace during the 2nd quarter valued at $31,000. Kilter Group LLC bought a new position in shares of Medpace during the second quarter valued at about $31,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Medpace in the 2nd quarter worth approximately $34,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO August Troendle sold 21,966 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the sale, the chief executive officer directly owned 338,225 shares in the company, valued at $211,549,590.75. This represents a 6.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders have sold 336,140 shares of company stock worth $208,008,328. Insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

MEDP has been the topic of a number of research reports. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Truist Financial lifted their target price on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Barclays boosted their price target on Medpace from $600.00 to $625.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Weiss Ratings upgraded Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Finally, TD Cowen raised their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $607.73.

Medpace Stock Performance

Shares of MEDP stock traded up $10.49 during trading hours on Tuesday, reaching $630.15. The company had a trading volume of 128,838 shares, compared to its average volume of 325,251. The firm has a market cap of $17.59 billion, a PE ratio of 36.94, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18. The business has a fifty day moving average price of $606.76 and a 200-day moving average price of $533.55. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.